Form 8-K - Current report:
SEC Accession No. 0001842952-24-000022
Filing Date
2024-04-01
Accepted
2024-04-01 07:32:22
Documents
15
Period of Report
2024-04-01
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cntx-20240401.htm   iXBRL 8-K 26172
2 EX-99.1 a20240401-indfilingxrelease.htm EX-99.1 12484
6 image_0.jpg GRAPHIC 198753
  Complete submission text file 0001842952-24-000022.txt   451928

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20240401.xsd EX-101.SCH 1937
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20240401_lab.xml EX-101.LAB 24372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20240401_pre.xml EX-101.PRE 14143
18 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20240401_htm.xml XML 3000
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

EIN.: 863738787 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40654 | Film No.: 24805545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)